ENGN Stock Price Chart
ENGN Price
enGene Therapeutics Inc
$1.72
-80.56%
$-7.13
At close: May 07, 16:00:00 GMT-4
$1.71
-0.04%
$0
Post-market: May 07, 18:38:08 GMT-4
Back
enGene Therapeutics Inc (ENGN) Price
Key Stats
Prev.Close
$8.85
Open
$2.14
Day's Range
$1.7 - $2.24
52 week range
$1.71 - $12.25
Volume
23.4M
Avg.Volume
401.2K
Dividend yield
--
EPS (TTM)
-2.25
Market Cap
$115.1M
What is ENGN?
enGene Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. The company is headquartered in Saint-Laurent, Quebec and currently employs 45 full-time employees. The company went IPO on 2021-12-10. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).
